Traders should prepare for potential volatility following the March 12 earnings call, but this release itself contains no actionable financial information. Monitor for updates on clinical trial progress, cash runway, or changes in development strategy during the upcoming call.
CRVS drugs
CRVS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 6 $15.80entry
- T+1 · 8mo ago +0.60%α −0.24% · $15.89
- T+5 · 8mo ago −3.01%α −1.48% · $15.32
- T+20 · 8mo ago −6.87%α −4.82% · $14.71
- T+60 · 6mo ago −23.52%α −36.30% · $12.08
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Corvus Pharmaceuticals announced plans to host a conference call on March 12, 2026, to discuss its fourth quarter 2025 financial results and provide a business update. The press release contains no actual financial data, guidance, or material operational updates, only logistical details for the upcoming earnings call.
Key Facts
- Corvus Pharmaceuticals will report Q4 2025 financial results on March 12, 2026.
- The company will host a conference call and webcast at 4:30 pm ET.
- No financial results, metrics, or business updates were disclosed in this release.
- The company remains in clinical-stage development with soquelitinib in Phase 3 for PTCL and Phase 1 for atopic dermatitis.
Financial Impact
No financial data disclosed
Risk Factors
- Lack of disclosed financials increases uncertainty ahead of earnings.
- As a clinical-stage biotech, Corvus is dependent on trial outcomes and funding, with no near-term revenue from product sales.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250632 |
Track record
15 reports on CRVS
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +2.61% at T+1 after the Mar 12, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 13, 20263d ago Insider Buy Neutral 3/10 Entry $11.20 Now $10.60 −5.36% settles Feb 12
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $11.37 Now $10.60 −6.77% settles Feb 8
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $10.54 Now $10.60 +0.57% settles Feb 4
- Nov 5, 202611d ago Press Release Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $10.57 Now $10.60 +0.28% settles Feb 2
- Sep 30, 20266w ago Press Release Neutral 3/10 Entry $10.93 Now $10.60 −3.02% settles Dec 28
- Aug 21, 202612w ago Institutional Cluster Bullish 6/10 Entry $14.46 to $10.60 Now $10.60 −26.69% ▼ −26.69% −23.33% vs SPY
- Jul 22, 202616w ago 8-K Neutral 2/10 Entry $13.68 to $9.85 Now $10.60 −22.51% ▼ −28.00% −32.55% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $11.60 to $14.39 Now $10.60 −8.62% ▲ +24.05% +19.66% vs SPY
- May 14, 202626w ago 8-K Bullish 7/10 Entry $13.66 to $13.74 Now $10.60 −22.37% ▲ +0.62% −2.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers